Sorafenib tosylate in advanced kidney cancer: Past, present and future

Anti-Cancer Drugs

Volumn 20, Issue 6, 2009, Pages 409-415

  Porta, Camillo ^a   Paglino, Chiara ^a   Imarisio, Ilaria ^a   Ferraris, Elisa ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Advanced disease; Kidney cancer; Sorafenib

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; EVEROLIMUS; GELDANAMYCIN; GEMCITABINE; INTERFERON; INTERLEUKIN 2; INTERLEUKIN 21; PERIFOSINE; PHOSPHOTRANSFERASE; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RAF PROTEIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ALOPECIA; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; KIDNEY CANCER; KIDNEY CARCINOMA; LYMPHOCYTOPENIA; NAUSEA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN EXFOLIATION; SKIN MANIFESTATION; SKIN TOXICITY; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 67249141051     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32831fb500     Document Type: Review

References (55)

1. Hahn O, Stadler W. Sorafenib. Curr Opin Oncol 2006; 18:615-621.
2. Gollob JA, Wilhelm S, Carter C, Kelley SL. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 2006; 33:392-406. (Pubitemid 44142735)
3. Tian S, Mewani RR, Kumar D, Li B, Danner MT, Ahmad I, et al. Interaction and stabilization of X-linked inhibitor of apoptosis by Raf-1 protein kinase. Int J Oncol 2006; 29:861-867.
4. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-7109. (Pubitemid 39331023)
5. Adnane L, Trail PA, Taylor I, Wilhelm SM. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 2005; 407:597-612.
6. Guo K, Liu Y, Zhou H, Dai Z, Zhang J, Sun R, et al. Involvement of protein kinase C beta-extracellular signal-regulating kinase/p38 mitogen-activated protein kinase-heat shock protein 27 activation in hepatocellular carcinoma cell motility and invasion. Cancer Sci 2008; 99:486-496. (Pubitemid 351228564)
7. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23:965-972. (Pubitemid 46202316)
8. Moore M, Hirte HW, Siu L, Oza A, Hotte SJ, Petrenciuc O, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005; 16:1688-1694. (Pubitemid 41510145)
9. Awada A, Hendlisz A, Gil T, Bartholomeus S, Mano M, de Valeriola D, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005; 92:1855-1861. (Pubitemid 40826133)
10. Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005; 11:5472-5480. (Pubitemid 41060823)
11. Freidlin B, Simon R. Evaluation of randomized discontinuation design. J Clin Oncol 2005; 23:5094-5098. (Pubitemid 46224017)
12. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:2505-2512. (Pubitemid 46630627)
13. Escudier B, Szczylik C, Eisen T, Stadler WM, Schwartz B, Shan M, Bukowski RM. Randomized phase III trial of the Raf kinase and VEGFR inhibitor Sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) [abstract]. J Clin Oncol 2005;23 (Suppl):4510.
14. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebeis M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-134. (Pubitemid 46089673)
15. Eisen T, Bukowski RM, Staehler M, Szczylik C, Oudard S, Stadler WM, et al. Randomized phase III trial of Sorafenib in advanced renal cell carcinoma (RCC): impact of crossover on survival [abstract]. J Clin Oncol 2006; 24 (Suppl):4524.
16. Bukowski RM, Eisen T, Szczylik C, Stadler WM, Simantov R, Shan M, et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis [abstract]. J Clin Oncol 2007; 25 (Suppl):5023.
17. Porta C, Paglino C, Imarisio I, Bonomi L. Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of Sorafenib and Sunitinib. Clin Exp Med 2007; 7:127-134.
18. Beck J, Verzoni E, Negrier S, Keiholz U, Szczylik C, Bracarda S, et al. A large, open-label, non-comparative, phase III study of the multi-targeted kinase inhibitor Sorafenib in European patients with advanced renal cell carcinoma [abstract]. Eur Urol 2008; 7 (Suppl):694.
19. Knox JJ, Figlin RA, Stadler WM, McDermott DF, Gabrail N, Miller WH, et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacy [abstract]. J Clin Oncol 2007; 25 (Suppl):5011.
20. Porta C, Imarisio I, Paglino C. Re: Damien Pouessel, Stéphane Culine. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the Vascular Endothelial Growth Factor Receptor. Eur Urol 2008; 53:1092-1093.
21. Pouessel D, Culine S. High Frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the Vascular Endothelial Growth Factor Receptor. Eur Urol 2008; 53:376-381. (Pubitemid 350296582)
22. Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390.
23. Szczylik C, Demkow T, Staehler M, Rolland F, Negrier S, Hutson TE, et al. Randomized phase II trial of first-line treatment with Sorafenib versus Interferon in patients with advanced renal cell carcinoma: final results [abstract]. J Clin Oncol 2007; 25 (Suppl):5025.
24. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124. (Pubitemid 46089672)
25. Escudier B, Pluzanska A, Koraleski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial, Lancet 2007; 370:2103-2111.
26. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271-2281. (Pubitemid 46849157)
27. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of Everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet 2008; 372:449-456.
28. Rini BI, Hutson TE, Elson P, Garcia JA, Gilligan T, Nemec C, et al. A prospective trial of Sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior Sunitinib or Bevacizumab [abstract]. Genitourinary Cancer Symp 2008; p. 346.
29. Imarisio I, Ferraris E, Paglino C, Di Cesare P, Vercelli A, Serassi M, Porta C. Sequential use of Sorafenib and Sunitinib in advanced renal cell carcinoma (ARCC) patients: retrospective analysis in 42 patients from a single Center [abstract]. Ann Oncol 2008; 19 (Suppl 9):ix48.
30. Tamaskar I, Garcia JA, Elson P, Wood L, Mekhail T, Dreicer R, et al. Antitumor effects of Sunitinib or Sorafenib in patients with metastatic renal cell carcinoma who received prior aniangiogenic therapy. J Urol 2008; 179:81-86. (Pubitemid 350216728)
31. Dham A, Dudek AZ. Sequential therapy with Sorafenib and Sunitinib in renal cell carcinoma [abstract]. J Clin Oncol 2007; 25 (Suppl):5106.
32. Sablin MP, Bouaita L, Balleyguier C, Gautier J, Celier C, Balcaceres JL, et al. Sequential use of Sorafenib and Sunitinib in renal cancer: retrospective analysis in 90 patients [abstract]. J Clin Oncol 2007; 25 (Suppl):5038.
33. Takimoto CH, Awada A. Safety and anti-tumor activity of Sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol 2008; 61:535-548.
34. Gollob J, Richmond T, Jones J, Rathmell WK, Grigson G, Watkins C, et al. Phase II trial of Sorafenib plus Interferon-alpha 2b [IFN-(alpha)2b] as first- or second-line therapy in patients (pts) with metastatic renal cell cancer (RCC) [abstract]. J Clin Oncol 2006; 24 (Suppl):4538.
35. Ryan CW, Goldman BH, Lara PN Jr, Beer TM, Drabkin HA, Crawford E. Sorafenib plus interferon-[alpha]2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412 [abstract]. J Clin Oncol 2006; 24 (Suppl):4525.
36. Escudier B, Lassau N, Angevin E, Soria JC, Chami L, Lamuraglia M, et al. Phase I trial of Sorafenib in combination with Interferon alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 2007; 13:1801-1809. (Pubitemid 46952949)
37. Bracarda S, Porta C, Boni C, Santoro A, Artioli F, Contu A, et al. Randomized prospective phase II trial of two schedules of Sorafenib daily and Interferon-a2a (IFN) in metastatic renal cell carcinoma (MRCC) (RAPSODY): GOIRC study 0681 [abstract]. Genitourinary Cancer Symp 2008; p. 357.
38. Tannir NM, Zurita AJ, Heymach JV, Tran HT, Pagliaro LC, Corn P, et al. A randomized phase II trial of Sorafenib versus Sorafenib plus low-dose Interferon-alfa: clinical results and biomarker analysis [abstract]. J Clin Oncol 2008; 26 (Suppl):5093.
39. Bhatia S, Curti BD, Gordon MS, Quinn DI, Thompson JA, DeVries TA, et al. Recombinant IL-21 (rIL-21) in combination with Sorafenib: interim results from a phase 1/2 study in patients with metastatic renal cell cancer (mRCC) [abstract]. J Clin Oncol 2008; 26 (Suppl):16008.
40. Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, et al. Combination therapy with Sorafenib and Bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008; 26:3709-3714.
41. Sosman JA, Flaherty KT, Atkins MB, McDermott DF, Rothenberg ML, Vermeulen WL et al. Updated results of a phase I trial of Sorafenib (S) and Bevacizumab (B) in patients with metastatic renal cell cancer (mRCC) [abstract]. J Clin Oncol 2008; 26 (Suppl):5011.
42. Giessinger S, Amato RJ, Jac J, Saxena S, Willis JP, Chiang SB. A phase I study with a daily regimen of the oral mTOR inhibitor RAD001 (Everolimus) plus Sorafenib for patients with metastatic renal cell cancer (MRCC) [abstract]. J Clin Oncol 2008; 26 (Suppl):14603.
43. Rosenberg JE, Weinberg VK, Claras C, Ryan C, Lin AM, Fong L, et al. Phase I study of Sorafenib and RAD001 for metastatic clear cell renal cell carcinoma [abstract]. J Clin Oncol 2008; 26 (Suppl):5109.
44. Kumar S, Marks RS, Richardson R, Quevedo F, Croghan GA, Markovic SN, et al. A phase I study of the raf kinase/VEGF-R inhibitor Sorafenib in combination with Bortezomib in patients with advanced malignancies [abstract]. J Clin Oncol 2008; 26 (Suppl):2569.
45. Patnaik A, Ricart J, Cooper K, Papadopoulos K, Beeram M, Mita C, et al. A phase I, pharmacokinetic and pharmacodynamic study of Sorafenib (S), a multi-targeted kinase inhibitor, in combination with Temsirolimus (T), an mTOR inhibitor in patients with advanced malignancies [abstract], J Clin Oncol 2007; 25 (Suppl):3512.
46. Schreeder MT, Figlin RA, Stephenson JJ, Campos L, Chawla SP, Spigel DR, et al. Phase I multicenter trial of Perifosine in combination with Sorafenib for patients with advanced cancers including renal cell carcinoma [abstract]. J Clin Oncol 2008; 26 (Suppl):16024.
47. Tomasello L, Sertoli MR, Rubagotti A, Guglielmini P, Tacchini L, Bedognetti D, et al. Combination of Sorafenib and weekly Gemcitabine in patients (pts) with metastatic renal cell cancer (MRCC): a phase II study, preliminary results [abstract]. J Clin Oncol 2008; 26 (Suppl):16011.
48. Jeske S, Tagawa ST, Milowsky MI, Matulich D, Kung S, Sung MW, et al. Sorafenib (S) plus Gemcitabine (GEM) and Capecitabine (CAP) for advanced renal cell carcinoma (RCC): updated phase I results from a phase I/II trial (NCI 6981) [abstract]. J Clin Oncol 2008; 26 (Suppl):16023.
49. Vaishampayan UN, Sausville E, Heilbrun LK, Quinn M, Burger A, Ivy P, et al. Phase I trial of oral Sorafenib (S) and intravenous 17-allyl-amino- geldanamycin (A) in advanced malignancies: safety and efficacy in metastatic renal cancer (RCC) [abstract]. Genitourinary Cancer Symp 2008; p. 368.
50. Amato RJ, Jac J, Harris P, Dalton M, Saxena S, Monzon F, et al. A phase II trial of intra-patient dose escalated Sorafenib in patients (pts) with metastatic renal cell cancer (MRCC) [abstract]. J Clin Oncol 2008; 26 (Suppl):5122.
51. Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger AS, Mulders PF, Patard JJ, et al. Renal cell carcinoma guideline. Eur Urol 2007; 51:1502-1510. (Pubitemid 46634775)
52. Porta C, Paglino C, Imarisio I. Algorithm for systemic therapies in metastatic kidney cancer in the era of targeted therapies. Kidney Cancer Int 2007; 5:57-60.
53. Eisen T, Oudard S, Szczylik C, Gravis G, Heinzer H, Middleton R, et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst 2008; 100:1454-1463.
54. Porta C, Bracarda S, Beck J, Procopio G, Staehler M, Strauss UP, et al. Efficacy and safety of Sorafenib in elderly pts: results from a large open-label, non-comparative phase III study in European pts with advanced RCC (EU ARCCS) [abstract]. Ann Oncol 2008; 19 (Suppl 8):viii193.
55. Escudier B. Sorafenib in kidney cancer. Ann Oncol 2007; 18 (Suppl 9):ix90-93.